Advanced Filters
noise
Found 842 clinical trials
N Nadia Bolognini, PhD

Advances in Neuropsychological Diagnostics

This project is aimed at advancing neuropsychological diagnostics, enriching and modernizing the panorama of both clinical and forensic psychometric testing. The rapid socio-demographic changes, the developments of neuropsychological semiotics and nosography, as well as the growing applicative specialization of neuropsychological assessment make it necessary to introduce further tools to satisfy …

20 - 100 years of age All Phase N/A
D Daniel J van Wamelen, PhD

IMarkHD: in Vivo Longitudinal Imaging of HD Pathology

iMarkHD is an adaptive, longitudinal positron emission tomography (PET) and magnetic resonance (MR) imaging study in Huntington's disease (HD) that aims to assess abnormal molecular, functional, and structural changes in participants' brains, ranging from several years before symptom onset to the advanced symptom stage. The study will be conducted over …

21 - 75 years of age All Phase N/A
A Andrew C Frisina, M.S.

Prospective Single-Timepoint Huntington's Disease Biospecimen Collection Study

OBJECTIVES The primary study objective is to collect blood from participants with Huntington's Disease in order to validate a CE marked Cytosine, Adenine, Guanine (CAG) assay for use in future studies for Huntington's Disease. The secondary study objective is to create a biorepository that can be used to identify disease …

25 - 65 years of age All Phase N/A
L Lauri Jennisch, MS

Child to Adult Neurodevelopment in Gene Expanded Huntington's Disease

Huntington's Disease (HD) is an autosomal dominant disease manifested in a triad of cognitive, psychiatric, and motor signs and symptoms. HD is caused by a triplet repeat (CAG)expansion in the gene Huntingtin (HTT). This disease has classically been conceptualized as a neurodegenerative disease. However, recent evidence suggests that abnormal brain …

6 - 30 years of age All Phase N/A
A Amoy Fraser, PhD, CCRP, PMP

Extracellular Vesicles for HD

The primary objective of this study is to discover blood-based biomarker of brain Huntingtin (HTT) protein using extracellular vesicles to be used in evaluating target engagement in HTT lowering clinical trials. Secondary objectives of this study include developing more accurate biomarkers of Huntington disease (HD) progression or conversion and to …

18 - 75 years of age All Phase N/A
M Minhtrang Chu, Study Coordinator

Huntington's Disease Biobank: Advancing Remote Monitoring and Deep Phenotyping

This observational study aims to identify novel biomarkers of disease onset and progression in Huntington's disease by integrating remote monitoring with fluid biomarkers. Using video-based computer vision and mobile app-based cognitive assessments combined with machine learning algorithms, we aim to develop markers that can be used by Huntington's disease patients …

years of age All Phase N/A
A Amoy Fraser, PhD, CCRP, PMP

Gut Microbiomes in HD

The purpose of this study is to find out if there is a connection between the naturally occurring bacteria in our bodies and the progression of Huntington disease. The investigators are trying to determine if patients who are diagnosed with adult-onset HD and who exhibit a rapid rate of disease …

18 years of age All Phase N/A

Cognitive Assessment Tools for Huntington's Disease.

The purpose of the current proposal is to expand understanding of two currently available cognitive tools that are not typically used in Huntington Disease (HD) clinical trials that might be useful both for initial screening and for clinical trial application. One is the Coding Test and the other is the …

30 - 65 years of age All Phase N/A
M Moira Marizzoni

Exploring the Gut-Brain Axis in Ageing and Neurodegeneration

Neurodegenerative diseases are a major health concern due to their growing societal implications and economic costs. The identification of early markers of pathogenic mechanisms is one of the current main challenges. The gut-brain axis has become a primary target because of its transversal role across the neurodegenerative spectrum and its …

20 - 90 years of age All Phase N/A
S Sugitha Maheswaran, BS

Digital Measures for Clinical Trial Endpoints in Huntington's Disease

MEND-HD is a longitudinal study evaluating the feasibility of passive monitoring of gait and chorea in patients with HD and the meaningfulness of these outcomes for patients with HD and their care partners/support persons. Participants will take part in four virtual visits with study investigators to answer survey questions on …

25 - 60 years of age All Phase N/A

Simplify language using AI